BioCryst Pharmaceuticals Inc., of Birmingham, Ala., named Elliott T. Berger senior vice president of regulatory affairs.

BioLineRx Ltd., of Jerusalem, appointed Tamar Howson, Gil Bianco and Ilan Leviteh to its board of directors.

Bradmer Pharmaceuticals Inc., of Toronto, named Alan M. Ezrin chief executive officer and Brian Brohman chief business officer.

IntelGenx Technologies Corp., of Saint Laurent, Quebec, named James Wittenberg vice president of business development and Gino Di Iorio chief financial officer.

London Genetics Ltd., of London, named Mark Caulfield chairman of its scientific advisory board. The company also named Tim Aitman, Alan Ashworth, Aroon Hingorani, Ellen Solomon, Brendan Wren, Nick Carter and Shirley Hodgson to the board.

Medivation Inc., of San Francisco, appointed Robert Elfont vice president of clinical development.

NeurAxon Inc., of Waltham, Mass., appointed Robert Medve chief medical and regulatory officer.

Neurotech Pharmaceuticals Inc., of Lincoln, R.I., appointed Richard Small vice president and chief financial officer.

Sapphire Therapeutics Inc., of Bridgewater, N.J., named Eleanor de Groot vice president of technical operations and Brenda Marczi vice president of regulatory affairs. The company also appointed Richard V. Nelson vice president of project planning and management.

Theratechnologies, of Montreal, appointed Pierre Caudrelier chief medical officer.

Tikvah Therapeutics Inc., of Atlanta, named Jack W. Callicutt vice president and chief financial officer.